Syros Pharmaceuticals focused on hematologic malignancies and provided updates on its clinical progress, including the passing of the interim futility analysis for the primary endpoint in the Phase 3 SELECT-MDS-1 trial for tamibarotene. The company anticipates pivotal data by mid-2024. Additionally, tamibarotene has received Fast Track Designation from the FDA for treating unfit AML, with further data from the Phase 2 SELECT-AML-1 trial expected in the third quarter.

Syros remains committed to advancing tamibarotene toward key milestones in 2024. It has completed enrollment for the Phase 3 SELECT-MDS-1 trial and is preparing for the New Drug Application filing and potential launch in the United States.

To raise awareness, Syros will host a webcast on June 25, 2024, featuring medical experts discussing HR-MDS and the Phase 3 SELECT-MDS-1 trial’s design, highlighting the potential of tamibarotene for patients with RARA overexpression.

Syros has amended its Loan Agreement with Oxford Finance LLC to increase available term loans, providing financial flexibility for its ongoing clinical and pre-commercial activities. The company’s financial results for the March 31, 2024 quarter were also reported.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.